← Leaderboards
Stephen B. Hanauer
University Of Chicago
$1,604,461
Attributed
$1,604,461
Total exposure
7
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,604,461 · 7
By mechanism
R01$762,331 · 1
U01$743,793 · 1
M01$98,337 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Judy H Cho$53,609,227
- Anna Birukova$12,956,677
- Eugene B Chang$58,954,761
- Karen Leigh Edelblum$8,422,013
- Clara Abraham$13,251,800
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationHuman SubjectClinical ResearchCrohn'S DiseaseGastrointestinal Disorder ChemotherapyDrug Screening /EvaluationMonoclonal AntibodyImmunotherapyIntravenous AdministrationCorticosteroidsRemission /RegressionDosageUlcerative ColitisBiomimeticsBlood ChemistryChemopreventionGlutathione PeroxidaseHormone TherapyLeadLongitudinal Human StudyOutcomes ResearchPharmacokineticsPrednisonePrognosis
Grant awards (17)
Multi-site Trial of Azathioprine Dosing in Crohn Disease$743,793
U01 · FY2004 · DK
Multi-site Trial of Azathioprine Dosing in Crohn Disease$762,331
R01 · FY2003 · DK
CDP571 IN STEROID DEPENDENT PATIENTS W/ CROHNS DISEASE$0
M01 · FY2002 · RR
CDP571 IN MODERATE TO SEVERE CROHNS DISEASE$0
M01 · FY2002 · RR
ANTI-TNFA MAB (REMICAD /INFLIXIMAB) IN ACTIVE CROHN'S DI$0
M01 · FY2002 · RR
ISIS 2302 IN STEROID-DEPENDENT CROHN'S DISEASE$0
M01 · FY2002 · RR
PHASE II STUDY OF BXT 51072 IN PATIENTS W/ ULCERATIVE COLITIS$0
M01 · FY2002 · RR
CDP571 IN MODERATE TO SEVERE CROHNS DISEASE$32,779
M01 · FY2000 · RR
PHASE II STUDY OF BXT 51072 IN PATIENTS W/ ULCERATIVE COLITIS$32,779
M01 · FY2000 · RR
CDP571 IN STEROID DEPENDENT PATIENTS W/ CROHNS DISEASE$32,779
M01 · FY2000 · RR
ANTI-TNFA MAB (REMICAD /INFLIXIMAB) IN ACTIVE CROHN'S DI$0
M01 · FY2000 · RR
ISIS 2302 IN STEROID-DEPENDENT CROHN'S DISEASE$0
M01 · FY2000 · RR
PHASE II STUDY OF BXT 51072 IN PATIENTS W/ ULCERATIVE COLITIS$0
M01 · FY2000 · RR
CDP571 IN STEROID DEPENDENT PATIENTS W/ CROHNS DISEASE$0
M01 · FY2000 · RR
CDP571 IN MODERATE TO SEVERE CROHNS DISEASE$0
M01 · FY2000 · RR
ISIS 2302 IN STEROID-DEPENDENT CROHN'S DISEASE$0
M01 · FY2000 · RR
ANTI-TNFA MAB (REMICAD /INFLIXIMAB) IN ACTIVE CROHN'S DI$0
M01 · FY2000 · RR